1. Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
   Erin R. Scheidemann et al, 2021, IJMS CrossRef
2. Pathogenesis of Penile Squamous Cell Carcinoma: Molecular Update and Systematic Review
   Inmaculada Ribera-Cortada et al, 2021, IJMS CrossRef
3. Prospects of using chondroprotectors for the treatment of pulmonary pathology
   I. Yu. Torshin et al, 2022, Farmakoèkonomika CrossRef
4. Key Role of Astrocytes in Postnatal Brain and Retinal Angiogenesis
   Mariela Puebla et al, 2022, IJMS CrossRef
5. Combinatorial targeting of Hippo-STRIPAK and PARP elicits synthetic lethality in gastrointestinal cancers
   Liwei An et al, 2022 CrossRef
6. Investigation of BRCA1 methylation and FAT3 mutation as a potential biomarker in ovarian cancer samples
   Manish Pratap Singh et al, 2022, Human Gene CrossRef
7. NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer
   Xiao-yang Gong et al, 2022, Front. Immunol. CrossRef
8. De novo 4q35.2 duplication containing FAT1 is associated with autism spectrum disorder
   Cristina Hernando‐Davalillo et al, 2022, Clinical Genetics CrossRef
9. The diverse functions of FAT1 in cancer progression: good, bad, or ugly?
   Zhuo Georgia Chen et al, 2022, J Exp Clin Cancer Res CrossRef
10. UV-Induced Somatic Mutations Driving Clonal Evolution in Healthy Skin, Nevus, and Cutaneous Melanoma
    Alba Loras et al, 2022, Life CrossRef
11. Repression and 3D-restructuring resolves regulatory conflicts in evolutionarily rearranged genomes
    Alessa R. Ringel et al, 2022, Cell CrossRef
12. The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy
    Marcos Paulo S. Damasio et al, 2022, Front. Oncol. CrossRef
13. Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes
    Martin Steinhoff et al, 2022, Seminars in Cancer Biology CrossRef
14. A pan-cancer analysis of the FAT1 in human tumors
    Ziyao Wang et al, 2022, Sci Rep CrossRef
15. Repurposed Drugs in Gastric Cancer
    Diana Araújo et al, 2022, Molecules CrossRef
16. A novel variant affecting the cytoplasmic tail of the FAT1 protocadherin causing coloboma and renal failure: A case report
    Emile R. Vieta-Ferrer et al, 2023, Ophthalmic Genetics CrossRef
17. Comprehensive Genomic Profiling Identifies FAT1 as a Negative Regulator of EMT, CTCs, and Metastasis of Hepatocellular Carcinoma
    Zi-Li Huang et al, 2023, JHC CrossRef
18. Association of FAT1 with focal epilepsy and correlation between seizure relapse and gene expression stage
    Dong-Fang Zou et al, 2023, Seizure CrossRef
19. Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma
    Hongyu Wang et al, 2023, Pathol. Oncol. Res. CrossRef
20. Somatic Variants and Exon-Level Copy Number Changes in Five Hyperplastic Oral Leukoplakias
    Anuhya Anne et al, 2022, Cytogenet Genome Res CrossRef
21. Predictive capacity of FAT1 transcriptional expression in patients with head and neck squamous cell carcinomas treated with radiotherapy
    Xavier León et al, 2023, Acta Otorrinolaringologica (English Edition) CrossRef
22. Intracranial hematolymphoid malignancies: A case series with molecular characterization
    Rebekah G. Langston et al, 2023, Clinical Neurology and Neurosurgery CrossRef
23. Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
    Jia Yee Lee et al, 2024, Biomedicine & Pharmacotherapy CrossRef
24. Clinical value of FAT1 mutations to indicate the immune response in colorectal cancer patients
    Wei Zhu et al, 2024, Genomics CrossRef
25. FAT1 upregulation is correlated with an immunosuppressive tumor microenvironment and predicts unfavorable outcome of immune checkpoint therapy in non-small cell lung cancer
    Chao Chen et al, 2024, Heliyon CrossRef
26. STAT1 mediated downregulation of the tumor suppressor gene PDCD4, is driven by the atypical cadherin FAT1, in glioblastoma
    Tipu Khan et al, 2024, Cellular Signalling CrossRef
27. Common skin cancers and their association with other non-cutaneous primary malignancies: a review of the literature
    Lindsay Holic, 2024, Med Oncol CrossRef
28. FAT1 inhibits the proliferation of DLBCL cells via increasing the m6A modification of YAP1 mRNA
    Tian-long Wang et al, 2024, Sci Rep CrossRef
29. Molecular pathways and targeted therapies in head and neck cancers pathogenesis
    Marian Constantin et al, 2024, Front. Oncol. CrossRef
30. Genetic testing of neoadjuvant therapy patients with esophageal cancer
    XiaoFeng Huang et al, 2024, Gene Reports CrossRef
31. Strategy of combining CDK4/6 inhibitors with other therapies and mechanisms of resistance
    Yingfei Xue, 2024, Int J Clin Exp Pathol CrossRef
32. Endometrial carcinomas with ambiguous histology often harbor TP53 mutations
    Ben Davidson et al, 2024, Virchows Arch CrossRef
33. Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study
    Ferdinando Clarelli et al, 2024, J Neurol CrossRef
34. Pediatric Angiosarcoma with Novel Phenotypic and Genotypic Profile in Chinese Children
    Bo Shao et al, 2024, Fetal and Pediatric Pathology CrossRef